XML 45 R31.htm IDEA: XBRL DOCUMENT
v3.21.1

Related Parties Transactions (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Related Party Transactions [Abstract] |
Schedule of related party transactions |
Name of entity or Individual |  | Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”) |  | Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”) |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”) |  | Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”) |  | Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang |  | Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’) |  | The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”) |  | Shareholder of the Company
Yoshinobu Odaira (the “Odaira”) |  | Director of the Company
GenePharm Inc. (the “GenePharm”) |  | Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) |  | Shareholder of the Company
LBG USA, Inc. (the “LBG USA”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”) |  | Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”) |  | Shareholder of the Company
|  | Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”) |  | An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan |  | Entity controlled by controlling beneficiary shareholder of ABVC
Schedule of amount due to related parties |
|  | March 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
GenePharm Inc. |  | $ | 142,225 |  |  | $ | 142,225 |
Amkey |  |  | 2,850 |  |  |  | 1,210 |
Total |  | $ | 145,075 |  |  | $ | 143,435 |
Schedule of amount due from related parties |
|  | March 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Rgene |  | $ | 43,266 |  |  | $ | 42,911 |
AsiaGene |  |  | 4,287 |  |  |  | 4,241 |
BioFirst (Australia) |  |  | 379,110 |  |  |  | 373,235 |
BioHopeKing Corporation |  |  | 121,848 |  |  |  | 123,583 |
LBG USA |  |  | 675 |  |  |  | 675 |
BioLite Japan |  |  | 150,000 |  |  |  | 150,000 |
Keypoint |  |  | 1,610 |  |  |  | 1,610 |
The Jiangs |  |  | 2,093 |  |  |  | - |
Total |  | $ | 702,889 |  |  | $ | 696,255 |
Schedule of amount due to related parties |
|  | March 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
BioFirst Corporation |  | $ | 23,647 |  |  | $ | 23,647 |
AsiaGene |  |  | 24,017 |  |  |  | - |
YuanGene |  |  | 9,205 |  |  |  | 9,205 |
The Jiangs |  |  | 18,750 |  |  |  | 16,627 |
Due to shareholders |  |  | 163,566 |  |  |  | 166,261 |
Due to employee |  |  | 72,967 |  |  |  | 72,704 |
Total |  | $ | 312,152 |  |  | $ | 288,445 |

X
- References No definition available. + Details
Name: | abvcd_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock
Namespace Prefix: | abvcd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Amount due to related party. + References No definition available. + Details
Name: | abvcd_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty
Namespace Prefix: | abvcd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration